Literature DB >> 35367479

An evidence-based review of the epidemiology of myopic traction maculopathy.

Kai Xiong Cheong1, Lingqian Xu1, Kyoko Ohno-Matsui2, Charumathi Sabanayagam3, Seang Mei Saw4, Quan V Hoang5.   

Abstract

Myopic traction maculopathy (MTM), one of the complications of pathologic myopia, is a spectrum of pathological conditions that are attributed to tractional changes in the eye characterized by retinoschisis, lamellar or full thickness macular hole, and foveal retinal detachment. Considering the global public health burden of MTM and pathologic myopia, it is important to understand these sight-threatening complications and their associations. We conducted an evidence-based review of the prevalence and natural history of MTM and associated risk factors. The prevalence of MTM in the general population is low, but is increased among high myopes. MTM is associated with preretinal tractional structures, myopic refractive error and axial elongation, posterior staphyloma, dome-shaped macula, chorioretinal atrophy, and myopic macular degeneration. The clinical course of MTM tends to be stable; however, MTM may progress, resulting in visual acuity deterioration, although spontaneous improvement also occurs. The associations of MTM progression include vitreous traction, location, and extent of MTM, and lamellar macular hole-specific factors. More high-quality population-based studies that assess MTM prevalence and natural history are needed.
Copyright © 2022. Published by Elsevier Inc.

Entities:  

Keywords:  Foveoschisis; Full thickness macular hole; High myopia; Lamellar macular hole; Maculoschisis; Myopic traction maculopathy; Natural history; Prevalence; Retinal detachment; Retinoschisis

Mesh:

Year:  2022        PMID: 35367479     DOI: 10.1016/j.survophthal.2022.03.007

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.197


  1 in total

1.  Effect of 0.01% atropine eyedrops on intraocular pressure in schoolchildren: a randomized clinical trial.

Authors:  Javaria Bukhari; Shi-Fei Wei; Shi-Ming Li; Wen-Zai An; Jia-Ling Du; Xin-Tong Liang; Jia-He Gan; Jia-Xin Tian; Wei-Ling Bai; Zhi-Ning Cai; Lei Yin; Ning-Li Wang
Journal:  Int J Ophthalmol       Date:  2022-09-18       Impact factor: 1.645

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.